Association of Increased Serum I-309 with Phenotypes, Disease Activity, and Cytokine Pattern in Primary Sjögren's Syndrome

Overview

Journal Clin Rheumatol

Publisher Springer

Date 2025 Jan 23

PMID 39849259

Authors

Yan Liang

Zhiyu Zhang

Jie Li

Zaixing Yang

Affiliations

Soon will be listed here.

Abstract

The aim of this study was to determine serum I-309 levels in primary Sjögren's syndrome (pSS) patients, as well as the association with disease phenotype, systemic activity, and T helper cell-related cytokines. A total of 58 pSS patients and 30 healthy controls (HC) were enrolled in this study. The concentrations of serum I-309, interleukin-4 (IL-4), IL-6, IL-9, IL-13, IL-17, IL-22, IL-23, tumor-necrosis factor-α (TNF-α), interferon-γ (IFN-γ), IFN-α, and IFN-β were measured with multiplex immunoassay. The relationships between I-309 and various clinical and laboratory variables were analyzed. The serum concentrations of I-309 were significantly increased (median, IQR, 14.24, 10.99--20.35, pg/ml) in pSS patients compared with HC (median, IQR, 8.27, 6.74--9.62, pg/ml) (P < 0.001). Serum I-309 is increased in pSS, and may be associated with systemic inflammation, Th1-, Th17,- and Th9 cells, type Key Points • Serum I-309 levels are increased in pSS patients. • Increased I-309 may be associated with systemic rather than local manifestations in pSS. • Increased I-309 may be associated with Th1, Th17 and Th9 other than Th2 in pSS. • There may be close relationships between I-309 and type land type II IFNs in pSS.

References

Brito-Zeron P, Kostov B, Solans R, Fraile G, Suarez-Cuervo C, Casanovas A . Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Ann Rheum Dis. 2014; 75(2):348-55. DOI: 10.1136/annrheumdis-2014-206418. View

Das S, Sarrou E, Podgrabinska S, Cassella M, Mungamuri S, Feirt N . Tumor cell entry into the lymph node is controlled by CCL1 chemokine expressed by lymph node lymphatic sinuses. J Exp Med. 2013; 210(8):1509-28. PMC: 3727324. DOI: 10.1084/jem.20111627. View

Haque N, Zhang X, French D, Li J, Poon M, Fallon J . CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells. Circulation. 2000; 102(7):786-92. DOI: 10.1161/01.cir.102.7.786. View

Liu S, Liu C, Lv X, Cui B, Yan J, Li Y . The chemokine CCL1 triggers an AMFR-SPRY1 pathway that promotes differentiation of lung fibroblasts into myofibroblasts and drives pulmonary fibrosis. Immunity. 2021; 54(9):2042-2056.e8. DOI: 10.1016/j.immuni.2021.06.008. View

Liu S, Zhang Z, Wang Y, Zhang Y, Min J, Li X . The chemokine CCL1 facilitates pulmonary fibrosis by promoting macrophage migration and M2 polarization. Int Immunopharmacol. 2023; 120:110343. DOI: 10.1016/j.intimp.2023.110343. View

Charo I, Ransohoff R . The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006; 354(6):610-21. DOI: 10.1056/NEJMra052723. View

Knipfer L, Schulz-Kuhnt A, Kindermann M, Greif V, Symowski C, Voehringer D . A CCL1/CCR8-dependent feed-forward mechanism drives ILC2 functions in type 2-mediated inflammation. J Exp Med. 2019; 216(12):2763-2777. PMC: 6888976. DOI: 10.1084/jem.20182111. View

Vila-Caballer M, Gonzalez-Granado J, Zorita V, Abu Nabah Y, Silvestre-Roig C, Del Monte-Monge A . Disruption of the CCL1-CCR8 axis inhibits vascular Treg recruitment and function and promotes atherosclerosis in mice. J Mol Cell Cardiol. 2019; 132:154-163. DOI: 10.1016/j.yjmcc.2019.05.009. View

Hernandez M, Starman E, Davis A, Withanage M, Zeng E, Lieberman S . A distinguishing profile of chemokines, cytokines and biomarkers in the saliva of children with Sjögren's syndrome. Rheumatology (Oxford). 2021; 60(10):4765-4777. PMC: 8487313. DOI: 10.1093/rheumatology/keab098. View

10.

Vitali C, Bombardieri S, Jonsson R, Moutsopoulos H, Alexander E, Carsons S . Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002; 61(6):554-8. PMC: 1754137. DOI: 10.1136/ard.61.6.554. View

11.

Seror R, Bootsma H, Saraux A, Bowman S, Theander E, Brun J . Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). Ann Rheum Dis. 2014; 75(2):382-9. DOI: 10.1136/annrheumdis-2014-206008. View

12.

Nguyen Y, Nocturne G, Henry J, Ng W, Belkhir R, Desmoulins F . Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts. Lancet Rheumatol. 2024; 6(4):e216-e225. PMC: 10949202. DOI: 10.1016/S2665-9913(23)00340-5. View

13.

Alunno A, Bartoloni E, Valentini V, La Paglia G, Valentini E, Leone M . Discrepancy between subjective symptoms, objective measures and disease activity indexes: the lesson of primary Sjögren's syndrome. Clin Exp Rheumatol. 2018; 36 Suppl 112(3):210-214. View

14.

Evans S, Repasky E, Fisher D . Fever and the thermal regulation of immunity: the immune system feels the heat. Nat Rev Immunol. 2015; 15(6):335-49. PMC: 4786079. DOI: 10.1038/nri3843. View

15.

Chen C, Liang Y, Zhang Z, Zhang Z, Yang Z . Relationships between increased circulating YKL-40, IL-6 and TNF-α levels and phenotypes and disease activity of primary Sjögren's syndrome. Int Immunopharmacol. 2020; 88:106878. DOI: 10.1016/j.intimp.2020.106878. View

16.

Mandl T, Bredberg A, Jacobsson L, Manthorpe R, Henriksson G . CD4+ T-lymphocytopenia--a frequent finding in anti-SSA antibody seropositive patients with primary Sjögren's syndrome. J Rheumatol. 2004; 31(4):726-8. View

17.

Mingueneau M, Boudaoud S, Haskett S, Reynolds T, Nocturne G, Norton E . Cytometry by time-of-flight immunophenotyping identifies a blood Sjögren's signature correlating with disease activity and glandular inflammation. J Allergy Clin Immunol. 2016; 137(6):1809-1821.e12. DOI: 10.1016/j.jaci.2016.01.024. View

18.

Asai A, Nakamura K, Kobayashi M, Herndon D, Suzuki F . CCL1 released from M2b macrophages is essentially required for the maintenance of their properties. J Leukoc Biol. 2012; 92(4):859-67. DOI: 10.1189/jlb.0212107. View

19.

Sironi M, Martinez F, DAmbrosio D, Gattorno M, Polentarutti N, Locati M . Differential regulation of chemokine production by Fcgamma receptor engagement in human monocytes: association of CCL1 with a distinct form of M2 monocyte activation (M2b, Type 2). J Leukoc Biol. 2006; 80(2):342-9. DOI: 10.1189/jlb.1005586. View

20.

Tamguney G, Van Snick J, Fickenscher H . Autocrine stimulation of rhadinovirus-transformed T cells by the chemokine CCL1/I-309. Oncogene. 2004; 23(52):8475-85. DOI: 10.1038/sj.onc.1207903. View